154 related articles for article (PubMed ID: 17149878)
1. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
Watts RE; Siegel M; Khosla C
J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
[TBL] [Abstract][Full Text] [Related]
2. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
4. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
Dafik L; Khosla C
Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
Klöck C; Herrera Z; Albertelli M; Khosla C
J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
Hausch F; Halttunen T; Mäki M; Khosla C
Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
[TBL] [Abstract][Full Text] [Related]
7. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Siegel M; Khosla C
Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
[TBL] [Abstract][Full Text] [Related]
9. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
Jasim MH; Rathbone DL
J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
[TBL] [Abstract][Full Text] [Related]
10. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
11. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D
J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409
[TBL] [Abstract][Full Text] [Related]
12. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
14. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2 undergoes a large conformational change upon activation.
Pinkas DM; Strop P; Brunger AT; Khosla C
PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Grosso H; Mouradian MM
Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
[TBL] [Abstract][Full Text] [Related]
17. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
18. Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.
Palanski BA; Khosla C
Biochemistry; 2018 Jun; 57(24):3359-3363. PubMed ID: 29570977
[TBL] [Abstract][Full Text] [Related]
19. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
20. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
